The Advocate: Supporting the Patient Voice has released its 2024 US Focused Patient Advocacy Report, offering an in-depth analysis of feedback from Patient Advocacy Organizations and Professional Societies/Associations in relation to the pharmaceutical community. This comprehensive report aims to help stakeholders understand new and innovative methods for collaborating with these organizations to enhance healthcare for all patients.
A standout finding in the report is that Johnson & Johnson (J&J) ranked first among over 100 companies for its advocacy efforts, securing top positions in five categories. J&J is recognized for its approach of 'moving beyond patient centricity to patient partner,' its willingness to collaborate beyond just funding, and its holistic approach to building relationships and identifying collaborative opportunities for patient benefit.
Amgen also showed significant progress, advancing in four out of five benchmarking categories. Patient advocates praised Amgen for being 'highly innovative and forward-thinking' and for its engagement at multiple levels with patient advocacy groups to listen, learn, and understand what is needed to advance patient treatments.
Pfizer has maintained its strong performance since 2019, placing second in both Advancing Patient Treatment and Patient/Professional Group Relations. The company is noted for its efforts in obtaining patient perspectives to advance care and improve access, as well as its commitment to patient support and education.
Sanofi has also demonstrated notable improvement, with patient advocates highlighting that its 'patient engagement is second to none.' Sanofi is commended for fostering health equity education by forming communities of practice groups among patient organizations.
Other notable organizations include AstraZeneca, which showed improvement in Policy Support; Eli Lilly, which excelled with Neurology groups; Merck, which achieved impressive rankings with Non-disease Specific groups; and Bristol-Myers Squibb, which led the way with Immunology groups.
The Advocate: Supporting the Patient Voice aims to deepen the understanding of the relationship between patient advocates and the pharmaceutical industry. Its mission is to ensure that patients remain at the center of all healthcare decisions, whether in a doctor's office, within a payer or PBM, or on Capitol Hill. The Advocate's syndicated market research offering provides valuable insights into the needs of patients and the patient advocate organizations that champion their causes.
Through its research and expertise, The Advocate guides pharmaceutical advocacy teams, aids in the development and implementation of patient-centric programs, and consults on incorporating the patient voice throughout the product lifecycle. For further information, visit www.TheBrooksGroupOnline.com.
